glp-1 and gip/glp-1 receptor agonists PDB-101: Molecule of the Month: Targeting GLP-1, GIP & GCG

Limitations The major limitations of the studies that are included in this systematic review are the enrollment of healthy subjects and insufficient data in conditions that might affect pharmacokinetics (e.g., kidney dysfunction)

Aims/hypothesis Regulators worldwide are reviewing safety data on glucagon-like peptide-1 receptor agonists (GLP-1RA), following reports by the Icelandic Medicines Agency in July 2023 of suicidal ideation and self-injury (SIS) in individuals taking liraglutide and semaglutide

Risk of bias was assessed using an adapted Quality Assessment Tool for In Vitro Studies (QUIN) tool

Strongest weight-loss data in its class.

A large global retrospective cohort study (n=331,863 matched patients

Available via online consultation with nationwide delivery from Yuushin Clinic, Sapporo.